Procter & Gamble Health Limited vs Zydus Lifesciences Limited
A side-by-side comparison of Procter & Gamble Health Limited (PGHL) and Zydus Lifesciences Limited (ZYDUSLIFE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
Procter & Gamble Health Limited vs Zydus Lifesciences Limited are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.
- Valuation22
- Profitability40
- Growth02
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
PGHL takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
ZYDUSLIFE takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
ZYDUSLIFE takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has been maintaining a healthy dividend payout of 104.1%", "Company is almost debt free."]
- − ["Stock is trading at 16.46 times its book value"]
- + ["Company has delivered good profit growth of 18.6% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 20.9%"]
- − []
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.